Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 68,536 shares changed hands during mid-day trading, an increase of 103% from the previous session's volume of 33,835 shares.The stock last traded at $14.08 and had previously closed at $14.58.
Analysts Set New Price Targets
Several equities research analysts have issued reports on TLX shares. HC Wainwright initiated coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target for the company. Wedbush restated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. Finally, William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th.
Get Our Latest Analysis on TLX
Telix Pharmaceuticals Trading Down 4.7%
The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The company has a fifty day moving average price of $16.44 and a 200 day moving average price of $16.97.
Hedge Funds Weigh In On Telix Pharmaceuticals
Large investors have recently bought and sold shares of the stock. ABC Arbitrage SA bought a new position in shares of Telix Pharmaceuticals in the first quarter worth approximately $451,000. Blair William & Co. IL bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $217,000. Finally, Private Advisor Group LLC purchased a new stake in Telix Pharmaceuticals during the 1st quarter valued at $170,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
